Daily Stock Opinions and Ratings

Opinions

Larry Berman CFA, CMT, CTAAptose BiosciencesAPS.TODON'T BUYSep 03, 2002

Volatile. In a downtrend. Probably getting near a low.

Larry Berman CFA, CMT, CTA

Unknown

Unlock Rating

$0.56

Stock price when the opinion was issued

$2.33

As of Jun 09, 2026. Market Open.

biotechnologypharmaceutical

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

PARTIAL BUY

Don't get scared of parabolic moves. The chart looks very good. It has shot up in the last 6 weeks. Its next move could be just under $6 pretty quickly. Relative strength vs. the S&P looks very good. However, expect volatility. Own a small holding.

RISKY

An old story, but re-invigorated by an impressive management team. Speculative. Recent sell off in biotech has not helped them.

SELL

At this point, it's a lottery ticket, so for a conservative, fundamental investor, he would call it a sell. Their therapy for pancreatic cancer hasn't been shown to be effective. Be very, very cautious over the next couple of months because it's an orphan stock and you are going into tax loss selling.

BUY

A very interesting company. Has always been a bit of a disappointment. Once they get their FDA approval then the stock should go.

BUY

One of the more undervalued of the biotech's. Have a number of interesting products that are being developed. Has been disappointed in the stock performance. Need some news that will push the valuation.

DON'T BUY

Have done well getting approvals on their products but the stock hasn't done very much. Would like to get rid of his holdings, but not at this price.

WEAK BUY

Not their favorite biotech. Cancer Institute has given them a lot of money for phase two studies. Possibly have a very elegant solution. Expect there will be a lot of news as phase two trials proceed. Volatile. Early stages so only buy a little.

DON'T BUY

Highly speculative. A very high number of shares outstanding. Trading below its 50/200 day moving average. Struggling to hold on to its current level. Have had 10 quarters of losses.

BUY

A very interesting stock at this price. Good cancer drugs. Still awaiting trial completions in the US. Also have new products.

BUY

Getting a lot of patent approvals. A growth story in the making. Have an extensive profile. Have recently flushed out their balance sheets with an issue. A very interesting story, but can be somewhat volatile.

DON'T BUY

High-risk company.You should own five or six in this sector in order to spread the risks.

BUY ON WEAKNESS

Charts indicate a risky stock. If you want to buy, pick a point 10/15% below its recent low.

BUY

Just did a financing to extend development on new products. Sees further improvement.

DON'T BUY

Has never generated any degree of profitability. Speculative.

BUY

Received patent approval on one of their processes. New drugs for cancer are being tested in Mexico and USA. You have to keep an eye on this one.

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Barry Schwartz

Baskin Wealth Management

Jim Cramer - Mad Money

CNBC